DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ventavis (Iloprost Inhalation) - Summary

 

-- advertisement --

VENTAVIS SUMMARY

Ventavis®
(iloprost) Inhalation Solution
Rx Only

Ventavis (iloprost) Inhalation Solution is a clear, colorless, sterile solution containing 10 mcg/mL iloprost formulated for inhalation via either of two pulmonary drug delivery devices: the I-neb™ AAD® (Adaptive Aerosol Delivery) System or the Prodose® AAD® System. Ventavis is supplied in 2 ampule configurations, a 2 mL and a 1 mL single-use glass ampule. Both ampule sizes contain 10 mcg/1 mL. Each mL of the aqueous solution contains 0.01 mg iloprost, 0.81 mg ethanol, 0.121 mg tromethamine, 9.0 mg sodium chloride, and approximately 0.51 mg hydrochloric acid (for pH adjustment to 8.1) in water for injection. The solution contains no preservatives.

Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms. In controlled trials, it improved a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration (see CLINICAL PHARMACOLOGY, Clinical Trials).

VENTAVIS NEWS HIGHLIGHTS

Published Studies Related to Ventavis (Iloprost Inhalation)

A randomized trial of iloprost in patients with intermittent claudication. [2008.02]

Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. [2008.01]

Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. [2007.11.01]

The treatment of venous leg ulcers: a new therapeutic use of iloprost. [2007.11]

An alternative agent for radial arterial graft spasm: application of topical iloprost. [2007.06]

more>>

Clinical Trials Related to Ventavis (Iloprost Inhalation)

Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis [Terminated]

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction [Terminated]

Aerosolized Randomized Iloprost Study II (AIR – II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension [Completed]

The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension [Active, not recruiting]

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension [Recruiting]

more>>

Page last updated: 2008-06-22

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008